
    
      Inclusion criteria

        -  All patients expected to be treated with aflibercept in combination with FOLFIRI for a
           mCRC, after failure of treatment with oxaliplatin + anti-EGFR on the decision of the
           doctor (situation included in the framework of the MA of aflibercept) .

        -  Age â‰¥18 years

        -  Signature of the agreement for the collection of medical and personal data. (Patients
           who have received FOLFIRINOX in the first line metastatic are allowed) Note: Failure is
           defined as progression during or within 6 months after discontinuation of oxaliplatin

      Exclusion criteria :

        -  Concurrent participation in a clinical trial

        -  Patients who have previously received anti-VEGF agents and / or aflibercept in one
           trial.

        -  Patients who received FOLFIRI in the first metastatic line.
    
  